
Patients with histopathologically or cytologically confirmed primary lung cancer of any stage or histology
Consent and randomisation within 6 weeks of tissue diagnosis (pathological report date) and before the start of treatment
Randomise
CONTROL ARM
Anticancer treatment according to local practice
(NO DALTEPARIN)
RESEARCH ARM
Anticancer treatment according to local practice and START DALTEPARIN as soon as possible and before first definitive anticancer treatment (1 x daily dalteparin 5,000 IU subcutaneous for 24 weeks)
Follow-up
Every 3-4 weeks from randomisation until the 24 week visit, then at 9 months and 1 year and at routine follow-up appointments thereafter
Primary outcome measure of the trial is overall survival
Secondary outcome measures are:
Venous thrombotic event free survival
Serious adverse events
Metastasis-free survival
Toxicity
Quality of life
Breathlessness
Anxiety and depression
Cost effectiveness
Cost utility